检索范围:
排序: 展示方式:
《医学前沿(英文)》 2022年 第16卷 第4期 页码 610-617 doi: 10.1007/s11684-021-0827-8
关键词: bevacizumab elderly patient advanced non-small-cell lung cancer overall survival toxicity
null
《医学前沿(英文)》 2013年 第7卷 第2期 页码 157-171 doi: 10.1007/s11684-013-0272-4
Non-small-cell lung cancer (NSCLC) is the most common cause of premature death among the malignant diseases worldwide. The current staging criteria do not fully capture the complexity of this disease. Molecular biology techniques, particularly gene expression microarrays, proteomics, and next-generation sequencing, have recently been developed to facilitate effectively its molecular classification. The underlying etiology, pathogenesis, therapeutics, and prognosis of NSCLC based on an improved molecular classification scheme may promote individualized treatment and improve clinical outcomes. This review focuses on the molecular classification of NSCLC based on gene expression microarray technology reported during the past decade, as well as their applications for improving the diagnosis, staging and treatment of NSCLC, including the discovery of prognostic markers or potential therapeutic targets. We highlight some of the recent studies that may refine the identification of NSCLC subtypes using novel techniques such as epigenetics, proteomics, or deep sequencing.
关键词: non-small-cell lung cancer molecular typing individualized medicine molecular-targeted therapy gene expression profiling
Fen LAN, Shengdao XIONG, Weining XIONG, Guopeng XU, Xiaoxia LU
《医学前沿(英文)》 2009年 第3卷 第1期 页码 41-44 doi: 10.1007/s11684-009-0009-6
关键词: Syk kinase carcinoma non-small-cell lung tumor suppressor protein p53
Jiahui Xu, Qianqian Wang, Elaine Lai Han Leung, Ying Li, Xingxing Fan, Qibiao Wu, Xiaojun Yao, Liang Liu
《医学前沿(英文)》 2020年 第14卷 第1期 页码 60-67 doi: 10.1007/s11684-019-0694-8
关键词: BPTF small molecule epigenetics non-small-cell lung cancer
《医学前沿(英文)》 2023年 第17卷 第1期 页码 18-42 doi: 10.1007/s11684-022-0976-4
关键词: non-small cell lung cancer driver mutations treatment strategy resistant mechanism immune-checkpoint inhibitors
Molecular markers and pathogenically targeted therapy in non-small cell lung cancer
Bo PENG BA , Jinnong ZHANG MD , Jamile S. WOODS MD , Wei PENG MD, PhD
《医学前沿(英文)》 2009年 第3卷 第3期 页码 245-255 doi: 10.1007/s11684-009-0044-3
关键词: lung cancer carcinoma non-small cell lung cancer molecular markers targeted therapy
null
《医学前沿(英文)》 2011年 第5卷 第1期 页码 53-60 doi: 10.1007/s11684-011-0121-2
Video-assisted thoracoscopic surgery (VATS) provides a new approach for treating early-stage lung cancer. Lobectomy by VATS has many advantages over conventional thoracotomy, such as shorter recovery time, less postoperative pain, and faster resumption of a normal lifestyle. However, there is still much debate on the role of VATS in lobectomy for the treatment of lung cancer. Concerns regarding safety, the extent of mediastinal lymph node dissection, and long-term survival have made some surgeons apprehensive of its validity for lung cancer. In this paper, we review the development of thoracoscopy, the present status of VATS for early stage of non-small cell lung cancer (NSCLC), and comparison between VATS and open thoracotomy in the management of NSCLC.
关键词: non-small cell lung cancer video-assisted thoracoscopic surgery lobectomy
CD47 blockade improves the therapeutic effect of osimertinib in non-small cell lung cancer
《医学前沿(英文)》 2023年 第17卷 第1期 页码 105-118 doi: 10.1007/s11684-022-0934-1
关键词: osimertinib anti-CD47 antibody combination strategy ADCP EGFR
null
《医学前沿(英文)》 2013年 第7卷 第4期 页码 462-476 doi: 10.1007/s11684-013-0270-6
Evaluating the effects of novel drugs on appropriate tumor models has become crucial for developing more effective therapies that target highly tumorigenic and drug-resistant cancer stem cell (CSC) populations. In this study, we demonstrate that a subset of cancer cells with CSC properties may be enriched into tumor spheroids under stem cell conditions from a non-small cell lung cancer cell line. Treating these CSC-like cells with gemcitabine alone and a combination of gemcitabine and the novel CHK1 inhibitor PF-00477736 revealed that PF-00477736 enhances the anti-proliferative effect of gemcitabine against both the parental and the CSC-like cell populations. However, the CSC-like cells exhibited resistance to gemcitabine-induced apoptosis. Collectively, the spheroid-forming CSC-like cells may serve as a model system for understanding the mechanism underlying the drug resistance of CSCs and for guiding the development of better therapies that can inhibit tumor growth and eradicate CSCs.
关键词: drug resistance cancer stem cell checkpoint kinase 1 (CHK1) PF-00477736 lung cancer tumorigenicity
Anlotinib as third- or further-line therapy for short-term relapsed small-cell lung cancer: subgroup
《医学前沿(英文)》 2022年 第16卷 第5期 页码 766-772 doi: 10.1007/s11684-021-0916-8
关键词: anlotinib chemotherapy short-term relapsed small-cell lung cancer
Orlistat induces ferroptosis-like cell death of lung cancer cells
《医学前沿(英文)》 2021年 第15卷 第6期 页码 922-932 doi: 10.1007/s11684-020-0804-7
Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy
Zhao Zhang, Jun Jiang, Xiaodong Wu, Mengyao Zhang, Dan Luo, Renyu Zhang, Shiyou Li, Youwen He, Huijie Bian, Zhinan Chen
《医学前沿(英文)》 2019年 第13卷 第1期 页码 57-68 doi: 10.1007/s11684-019-0683-y
Lung cancer is the most common incident cancer and the leading cause of cancer death. In recent years, the development of tumor immunotherapy especially chimeric antigen receptor T (CAR-T) cell has shown a promising future. Epidermal growth factor receptor variant III (EGFRvIII) is a tumor-specific mutation expressed in various types of tumors and has been detected in non-small cell lung cancer with a mutation rate of 10%. Thus, EGFRvIII is a potential antigen for targeted lung cancer therapy. In this study, CAR vectors were constructed and transfected into virus-packaging cells. Then, activated T cells were infected with retrovirus harvested from stable virus-producing single clone cell lines. CAR expression on the surfaces of the T cells was detected by flow cytometry and Western blot. The function of CAR-T targeting EGFRvIII was then evaluated. The EGFRvIII-CAR vector was successfully constructed and confirmed by DNA sequencing. A stable virus-producing cell line was produced from a single clone by limited dilution. The culture conditions for the cell line, including cell density, temperature, and culture medium were optimized. After infection with retrovirus, CAR was expressed on more than 90% of the T cells. The proliferation of CAR-T cells were induced by cytokine and specific antigen in vitro. More importantly, EGFRvIII-CART specifically and efficiently recognized and killed A549-EGFRvIII cells with an effector/target ratio of 10:1 by expressing and releasing cytokines, including perforin, granzyme B, IFN-g, and TNF-α. The in vivo study indicated that the metastasis of A549-EGFRvIII cells in mice were inhibited by EGFRvIII-CART cells, and the survival of the mice was significantly prolonged with no serious side effects. EGFRvIII-CART showed significantly efficient antitumor activity against lung cancer cells expressing EGFRvIII in vivo and in vitro. Therefore, CAR-T targeting EGFRvIII is a potential therapeutic strategy in preventing recurrence and metastasis of lung cancer after surgery.
关键词: chimeric antigen receptor T cells epidermal growth factor receptor lung cancer immunotherapy tumor immunology
Genomic variations in the counterpart normal controls of lung squamous cell carcinomas
null
《医学前沿(英文)》 2018年 第12卷 第3期 页码 280-288 doi: 10.1007/s11684-017-0580-1
Lung squamous cell carcinoma (LUSC) causes approximately 400 000 deaths each year worldwide. The occurrence of LUSC is attributed to exposure to cigarette smoke, which induces the development of numerous genomic abnormalities. However, few studies have investigated the genomic variations that occur only in normal tissues that have been similarly exposed to tobacco smoke as tumor tissues. In this study, we sequenced the whole genomes of three normal lung tissue samples and their paired adjacent squamous cell carcinomas. We then called genomic variations specific to the normal lung tissues through filtering the genomic sequence of the normal lung tissues against that of the paired tumors, the reference human genome, the dbSNP138 common germline variants, and the variations derived from sequencing artifacts. To expand these observations, the whole exome sequences of 478 counterpart normal controls (CNCs) and paired LUSCs of The Cancer Genome Atlas (TCGA) dataset were analyzed. Sixteen genomic variations were called in the three normal lung tissues. These variations were confirmed by Sanger capillary sequencing. A mean of 0.5661 exonic variations/Mb and 7.7887 altered genes per sample were identified in the CNC genome sequences of TCGA. In these CNCs, C:G→T:A transitions, which are the genomic signatures of tobacco carcinogen N-methyl-N-nitro-N-nitrosoguanidine, were the predominant nucleotide changes. Twenty five genes in CNCs had a variation rate that exceeded 2%, including ARSD (18.62%), MUC4 (8.79%), and RBMX (7.11%). CNC variations in CTAGE5 and USP17L7 were associated with the poor prognosis of patients with LUSC. Our results uncovered previously unreported genomic variations in CNCs, rather than LUSCs, that may be involved in the development of LUSC.
关键词: lung cancer counterpart normal control genomic variations
YANG Kunyu, LIU Li, ZHANG Tao, WU Gang, CAO Fengjun, WANG Jianhua
《医学前沿(英文)》 2007年 第1卷 第4期 页码 381-385 doi: 10.1007/s11684-007-0074-7
关键词: significant difference irradiation unresectable non-small-cell induction chemotherapy influence
The epidemic status and risk factors of lung cancer in Xuanwei City, Yunnan Province, China
null
《医学前沿(英文)》 2012年 第6卷 第4期 页码 388-394 doi: 10.1007/s11684-012-0233-3
Xuanwei City (formerly known as Xuanwei County) locates in the northeastern of Yunnan Province and is rich in coal, iron, copper and other mines, especially the smoky (bituminous) coal. Unfortunately, the lung cancer morbidity and mortality rates in this region are among China’s highest, with a clear upward trend from the mid-1970s to mid-2000s. In 2004–2005, the crude death rate of lung cancer was 91.3 per 100 000 in the whole Xuanwei City, while that for Laibin Town in this city was 241.14 per 100 000. The epidemiologic distribution (clustering patterns by population, time, and space) of lung cancer in Xuanwei has some special features, e.g., high incidence in rural areas, high incidence in females, and an early age peak in lung cancer deaths. The main factor that associates with a high rate of lung cancer incidence was found to be indoor air pollution caused by the indoor burning of smoky coal. To a certain extent, genetic defects are also associated with the high incidence of lung cancer in Xuanwei. Taken together, lung cancer in this smoky coal combustion region is a unique model for environmental factor-related human cancer, and the current studies indicate that abandoning the use of smoky coal is the key to diminish lung cancer morbidity and mortality.
关键词: lung cancer Xuanwei smoky coal combustion polycyclic aromatic hydrocarbons epidemiology
标题 作者 时间 类型 操作
Bevacizumab in combination with pemetrexed and platinum for elderly patients with advanced non-squamousnon-small-cell lung cancer: a retrospective analysis
期刊论文
Molecular classification of non-small-cell lung cancer: diagnosis, individualized treatment, and prognosis
null
期刊论文
Expression of Syk in non-small cell lung cancer and its relationship with clinicopathological parameters
Fen LAN, Shengdao XIONG, Weining XIONG, Guopeng XU, Xiaoxia LU
期刊论文
Compound C620-0696, a new potent inhibitor targeting BPTF, the chromatin-remodeling factor in non-small-celllung cancer
Jiahui Xu, Qianqian Wang, Elaine Lai Han Leung, Ying Li, Xingxing Fan, Qibiao Wu, Xiaojun Yao, Liang Liu
期刊论文
Treatment of advanced non-small cell lung cancer with driver mutations: current applications and future
期刊论文
Molecular markers and pathogenically targeted therapy in non-small cell lung cancer
Bo PENG BA , Jinnong ZHANG MD , Jamile S. WOODS MD , Wei PENG MD, PhD
期刊论文
Lobectomy by video-assisted thoracoscopic surgery (VATS) for early stage of non-small cell lung cancer
null
期刊论文
Combined gemcitabine and CHK1 inhibitor treatment induces apoptosis resistance in cancer stem cell-likecells enriched with tumor spheroids from a non-small cell lung cancer cell line
null
期刊论文
Anlotinib as third- or further-line therapy for short-term relapsed small-cell lung cancer: subgroup
期刊论文
Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy
Zhao Zhang, Jun Jiang, Xiaodong Wu, Mengyao Zhang, Dan Luo, Renyu Zhang, Shiyou Li, Youwen He, Huijie Bian, Zhinan Chen
期刊论文
Improved local control without elective nodal radiotherapy in patients with unresectable NSCLC treated by 3D-CRT
YANG Kunyu, LIU Li, ZHANG Tao, WU Gang, CAO Fengjun, WANG Jianhua
期刊论文